MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 275.4% from a year ago
Total assets stood at $418.79M at the end of Q1 FY2026, up 275.4% from a year earlier and down 12.7% from the prior quarter. Over 3 fiscal years it compounded at +130.0% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +275.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 479.51M USD
- Year-over-year change
- +250.2%
- 3-year CAGR
- +130.0%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 479.51M | +250.2% |
| FY2024 | 2024-12-31 | 136.92M | +49.8% |
| FY2023 | 2023-12-31 | 91.41M | +132.1% |
| FY2022 | 2022-12-31 | 39.39M | — |
Total Assets vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total assets of $418.79M is the 4th highest of the 11 companies compared; the peer median is $277.42M.
- Its year-over-year change of +275.4% is the 4th highest of 11, against a peer median of +63.0%.
- Over three fiscal years its annual growth of +130.0% compares with a peer median of +28.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $95.09B | +312490.6% | +21.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $1.07B | +353.4% | +37.3% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $497.6M | +64.7% | +153.1% |
| Mar 2026 | $418.79M | +275.4% | +130.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $393.48M | +1944.3% | +144.2% |
| Mar 2026 | $278.58M | +61.3% | +35.2% | |
| Mar 2026 | $276.26M | +60.7% | +53.7% | |
| Mar 2026 | $275.27M | -14.1% | +4.3% | |
| Mar 2026 | $225.63M | +176.3% | -0.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.88M | -40.1% | -23.5% |
| Dec 2025 | $132.99M | +7.2% | -12.1% | |
| Peer median (excluding MPLT) | $277.42M | +63.0% | +28.2% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.